Bigul

Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations

Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2022 ,inter alia, to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Friday, January 28, 2022 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2021, amongst other matters. Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. This is for your kind information and record purposes.
21-01-2022
Bigul

Strides Pharma Science Ltd - 532531 - Statement Of Investor Complaints For The Quarter Ended December 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 638431 Name of the Signatory :- Manjula RamamurthyDesignation :- Company Secretary and Compliance Officer
20-01-2022
Bigul

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Strides and its African subsidiary Universal Corporation partner with Medicines Patent Pool (MPP) to commercialize molnupiravir for the global markets
20-01-2022
Bigul

Strides Pharma Science Ltd - 532531 - Shareholding for the Period Ended December 31, 2021

Strides Pharma Science Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
20-01-2022
Bigul

Strides Pharma Science Ltd - 532531 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

Strides Pharma Science Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
18-01-2022
Bigul

Strides Pharma Science Ltd - 532531 - Voting Results Of Postal Ballot Pursuant To Regulation 44 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 And Scrutinizer'S Report.

Voting Results of Postal Ballot pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Scrutinizer's Report.
18-01-2022
Bigul

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Strides receives USFDA approval for Oseltamivir Phosphate for Oral Suspension
17-01-2022
Bigul

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Strides receives DCGI approval under EUA to commercialize Molnupiravir, an oral medication for Covid-19
28-12-2021
Bigul

Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 27, 2021 for Pronomz Ventures LLP
27-12-2021
Bigul

Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011on December 23, 2021 for Pronomz Ventures LLP
23-12-2021
Next Page
Close

Let's Open Free Demat Account